Blockchain
Breaking News
Bitcoin Gains Momentum as Biden Slaps Russia with Sanctions
Bitcoin entered the green zone after U.S. President Joe Biden revealed new sanctions meant to cut off Russia from western finance. (Read More)
Brazilian Senate Committee on Economic Affairs Approves Crypto Regulation Bill
Crypto regulation on Brazilian soil gained steam after the senate’s economic affairs committee approved a bill highlighting the ground rules and day-to-day usage of digital currency funds. (Read More)
NYSE Owner Purchases Stake in tZERO
New York Stock Exchange's (NYSE) parent company Intercontinental Exchange Inc (ICE) announced the purchase of a stake in tokenized securities venue tZERO. (Read More)
HKTDC welcomes 2022/23 Budget
HKTDC Chairman Dr Peter K N Lam said: "The pandemic has brought unprecedented challenges to SMEs in the past two years. The measures announced in this year's Budget, including enhancements to various export credit and SME financing schemes, can alleviate pressures on cash flow and operations. In addition, the various measures to support the IP (intellectual property) and technology sectors can also help SMEs tap into new markets and upgrade and transform their business.
"We are also encouraged that the HKSAR Government has allocated additional funding to support Hong Kong businesses pursuing development in the mainland. Through our network of mainland offices, we will work with partners including established Hong Kong business, professional services, and young entrepreneur associations in these cities, to organise training, exchange events, business missions and promotion campaigns.
"We believe this can help Hong Kong businesses in the mainland to expand and capture opportunities arising from the 'dual circulation' strategy and the Guangdong-Hong Kong-Macao Greater Bay Area, so as to better integrate into the nation's development." Dr Lam said.
In addition to the mainland market, the HKTDC will continue helping SMEs capture business opportunities in mature and emerging markets. Dr Lam said: "We will continue to help Hong Kong companies develop ASEAN (Association of Southeast Asian Nations) and mature markets with enhancements to our flagship overseas promotions such as 'Think Business, Think Hong Kong', as well as strengthen our online and offline platforms, business matching services, SME support schemes and other training activities, to help Hong Kong businesses connect with global enterprises and target relevant opportunities effectively. We are also glad to learn that the Government will actively consider attracting more conventions and exhibition events to be organised in Hong Kong when the pandemic subsides."
"Our team at the HTKDC will do all we can to create new opportunities for our industries, enabling them to diversify and find new impetus for recovery and growth amid the pandemic." Dr Lam added.
Media enquiries:
HKTDC's Communications & Public Affairs Department
Susanna Sin, Tel: +852 2584 4294, Email: susanna.kc.sin@hktdc.org
About HKTDC
The Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Follow us on Twitter @hktdc and LinkedIn
Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comThe Hong Kong Trade Development Council (HKTDC) welcomes the Hong Kong Special Administrative Region (HKSAR) 2022/23 Budget, including the additional funding to the Council for a support scheme for Hong Kong businesses in Mainland China, to help them capture opportunities under the National 14th Five-year Plan.
GaN Systems 3X Growth Drives Massive Expansion in Asia
GaN Systems' new office campus is in the Hsinchu Science Park, Taiwan, recognized as the center of semiconductor innovation and home to many of the world's leaders in advanced technology. It is also headquarters to GaN Systems' foundry partner, Taiwan Semiconductor Manufacturing Company (TSMC), the world's largest dedicated independent (pure-play) semiconductor foundry.
The new office center in Taiwan, GaN System's Asia-based headquarters, which opened with a few employees in 2015, has grown by more than 10X and will exceed 100 employees in the coming year. The space features a state-of-the-art research and design center with dedicated subject matter experts in the design and system validation of solutions for customers in several markets, including mobile phones, laptop P.C.s, data center power supplies, and automotive E.V. powertrain electronics. The enlarged R&D team will expand GaN Systems' industry-leading lineup of high-performance transistors and high-power modules and build upon its extensive range of reference designs for 65W, 100W, and 250W phone and computer chargers P.F.C., DCDC, and inverter designs for higher power markets.
"We're excited to expand our Asian footprint in Taiwan to accommodate GaN Systems' rapid growth," said Stephen Coates, Vice President, Global Operations and General Manager, Asia. "GaN Systems has grown tremendously, driven by the rapid adoption of GaN in consumer, industrial and automotive electronics. Our campus in Taiwan scales up our manufacturing, product and module design, and innovation footprint and expands support for our global customers and business partners. This 3X expansion demonstrates our commitment to Asia and to supporting the continued growth of Taiwan's semiconductor ecosystem."
Acceleration of the growth in Asia continues with the addition of Andy Chuang, GaN Systems' Vice President of Business Development. Mr. Chuang, based in the new Taiwan office, brings decades of wideband gap experience to the GaN Systems' team. Incremental to the expansion in Taiwan, GaN Systems' presence in Asia is also growing with success in India in e-mobility with applications in the two, three, and four-wheeler E.V. segments.
GaN Systems' imposing growth in the Asia region and internationally are proof of its recently announced USD $150 million growth capital funding round to accelerate innovation and adoption of GaN technology across its automotive, consumer, industrial, and enterprise markets. Global companies, including industry leaders like Dell, HARMAN, Siemens, Signify, and Philips, rely on GaN Systems' transistors to create reliable, best-in-class power transistors.
About GaN Systems
GaN Systems is the global leader in GaN power semiconductors with the most extensive transistors portfolio that uniquely addresses the needs of today's most demanding industries, including consumer electronics, data center servers, power supplies, renewable energy systems, industrial motors, and automotive electronics. As an industry-leading innovator, GaN Systems makes it possible to design smaller, lower cost, more efficient power systems. The company's award-winning products provide system design opportunities free from the limitations of yesterday's silicon. By changing the transistor performance rules, GaN Systems enables power conversion companies to revolutionize their industries and transform the world.
For more information, please visit: www.gansystems.com or on Facebook, Twitter and LinkedIn and scan this Q.R. code for our WeChat.
Media Inquiries:
Mary Placido
Trier and Company for GaN Systems
mary@triercompany.com
+1 (415) 218-3627
Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comGaN Systems, the global leader in GaN power semiconductors, announced today it has expanded its Asia presence with a 3X increase in its operation in Taiwan. With a 3X growth in revenue from the many consumer electronics, electric vehicles, and data centers & industrial power supply producers embracing GaN Systems power transistors, more people and space were necessary.
Lepu Biopharma Co., Ltd. Successfully Listed on the Main Board of HKEX
The share price of the Company closed at HK$7.14 per H share, with an intra-day high of HK$7.34 per H share. A total of approximately 15.8 million H shares were traded, with an aggregate turnover of approximately HK$112 million.
Lepu Biopharma is listed on the main board of HKEX, with 126,876,000 H shares being offered globally, including 12,688,000 Hong Kong Offer Shares, 114,188,000 International Placing Shares. The net proceeds received are estimated at approximately HK$804.2 million from the Global Offering, after deduction of underwriting fees, commissions and other estimated expenses payable by the Company in connection with the Global Offering. The net proceeds are intended for funding the core products, funding the other key clinical-stage drug candidates and the key pre-clinical drug candidates, acquiring potential technologies and assets and expand our pipeline of drug candidates, including discovery of new drug candidates and business development activities and to fulfill the continuous payment obligation under the acquisition of HX008 from HanX, and general corporate purposes.
Lepu Biopharma has three synergistic core technology platforms around its pipeline specializing in ADC technology, antibody discovery and advanced process and analytical development. The company also advances the clinical development of its candidates including ADC candidates, oncolytic virus candidates and combination therapies, plans to stay focused on the development of innovative products, create a pipeline for novel therapies, design and develop innovative products and build advanced technology platforms.
While Lepu Biopharma advancing its drug candidates, it has mapped out and is implementing the manufacturing and commercialization strategies. Company commenced the operation of a 2,000L GMP-compliant antibody production line in Beijing in 2019 in support of clinical trials for the antibody products. It is building a production line for oncolytic virus drugs in Beijing with a designed capacity of 200L, as well as a biologics manufacturing center in Shanghai Biotech Park, including a production line with a designed capacity of 12,000L initially, coupled with laboratories and manufacturing facilities, and one production line with capacity of 6,000L under construction.
The Founder, Chairman and Executive Director of Lepu Biopharma Co., Ltd. Dr. Pu Zhongjie said, "Today, we are very delighted to witness Lepu Biopharma to be officially listed on the Hong Kong Stock Exchange. This is an important milestone in our history of development as well as a starting point of our new journey. We sincerely appreciated the long-term trust and cooperation from customers and shareholders. We would also like to thank our partners, the Hong Kong Stock Exchange and the Securities and Futures Commission for all the great support. With solid R&D capabilities, advanced development platforms and comprehensive pipeline, we will seize the future trend of the whole industry, strengthen our position in the market with our competitive advantages and create greater value for shareholders and investors."
About Lepu Biopharma Co., Ltd.
Lepu Biopharma was incorporated in 2018 and is a biopharmaceutical company focusing on oncology therapeutics. The Company has designed pipeline with a range of oncology products. As of [the Latest Practicable Date], the Company had pipeline including eight clinical-stage drug candidates, three pre-clinical drug candidates and three clinical-stage combination therapies of the candidates in the pipeline. In addition, the Company focus on the development of innovative drugs including ADC and oncolytic virus. According to Frost & Sullivan, the Company house the leading ADC drug candidate pipeline in China in terms of the number of clinical-stage ADC drug candidates. As of [the Latest Practicable Date], the Company had initiated 28 clinical trials, among which three had entered registration trial phase and two were ongoing in the U.S. In terms of patents, as of [the Latest Practicable Date], Company had 11 issued patents in China, 20 in the U.S., nine in Japan, seven in the European Union and one in each of South Korea, Australia, Chile, India, Colombia, Indonesia, New Zealand and Israel, and 74 pending patent applications, consisting of 15 in Mainland China and 59 in overseas jurisdictions such as the U.S., Japan, India, South Korea, Australia, Israel, India and the European Union. Patentportfolio of the Company spans across mAb structure, targeted epitope, CMC, usage, biopharmaceutical formulation and indications.
For more information on Lepu Biopharma, please visit the website https://www.lepubiopharma.com/
Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comThe biopharmaceutical company focusing on oncology therapeutics - Lepu Biopharma Co., Ltd. ("Lepu Biopharma" or the "Company", stock code: 2157.HK), has successfully listed and commenced dealings on the Main Board of the Stock Exchange of Hong Kong Limited ("Hong Kong Stock Exchange") today
Latest Intelligence
